Photo from wikipedia
The mode of action by which the orphan drug anagrelide (1), a potent cAMP phosphodiesterase 3A inhibitor, reduces blood platelet count in humans is not well understood. Recent studies indicate… Click to show full abstract
The mode of action by which the orphan drug anagrelide (1), a potent cAMP phosphodiesterase 3A inhibitor, reduces blood platelet count in humans is not well understood. Recent studies indicate that 1 stabilizes a complex between PDE3A and Schlafen 12, protecting it from degradation while activating its RNase activity.
Keywords:
anagrelide clinically;
camp phosphodiesterase;
phosphodiesterase inhibitor
Journal Title: ACS medicinal chemistry letters
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: ACS medicinal chemistry letters
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!